Figure 3
Expression levels of IL-6, IL-8, and VEGF-A in TNBC cells and in BMEC cells following exposure to exosomes derived from TNBC cells. (a)–(c): Expression levels of IL-6, IL-8, and VEGF-A in MDA-MB-231 and MDA-MB-BrM2 cells: cell supernatant samples were prepared from breast cancer cells treated with vehicle control or with AM9928, as indicated and the levels of the human cytokines/chemokines were measured using specific ELISA assays for human IL-6, IL-8, and VEGF-A (R&D Systems ®ELISAs). Data shown are representative of at least three independent assays performed on triplicate wells. The error bars indicate standard deviations. *p < 0.05 as compared to vehicle control, **p < 0.005 as compared to vehicle control and ***p < 0.0005 as compared to vehicle control. (d)–(e): Expression levels of IL-8 and VEGF-A in HBMECs: Exosomes were isolated from either MDA-MB-231 or MDA-MB-231BrM2 cells treated with vehicle control or with AM9928 for 24 h as indicated. Exosomes were then isolated and were incubated with human BMECs in 3D-cocultures for 6 h. Supernatants from HBMECs were collected after 24 h and analyzed for IL-8 and VEGF-A using ELISA assays. Data shown are representative of at least three independent assays performed on triplicate wells. The error bars indicate standard deviations. *p < 0.05 in untreated exosomes derived from MDA-MB-231 cells or MDA-MB-231-BrM2 cells as compared to TNBC cells treated with AM9928 and **p < 0.005 as compared to HBMECs control, as indicated in the figure.
